Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 8-K (Current Report)
Date of Report: November 14, 2024
Reporting Period: The filing announces financial results for the three and nine months ended September 30, 2024.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) containing the detailed financial data. The filing text itself does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing text does not contain specific comparative data or details regarding material changes versus prior periods. Investors must refer to the attached press release for this information.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on November 14, 2024, detailing its financial results.
Legal Status of Information: The information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" under Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash burn figures for the three and nine months ended September 30, 2024.
- Verify the Company's cash position and runway based on the detailed financial statements referenced in the press release.
- Confirm any updates to clinical trial progress or strategic partnerships mentioned in the full press release.
- Note that the furnished information is not subject to the liabilities of Section 18 of the Exchange Act.